Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Advertising

Press Release

Curis to Release Fourth Quarter and Year-End 2017 Financial Results and Hold Conference Call on March 8, 2018

Curis,Inc.
Posted on: 01 Mar 18
Curis to Release Fourth Quarter and Year-End 2017 Financial Results and Hold Conference Call on March 8, 2018

PR Newswire

LEXINGTON, Mass., March 1, 2018

LEXINGTON, Mass., March 1, 2018 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development and commercialization of innovative and effective therapeutics for the treatment of cancer, today announced that the Company will release its fourth quarter and year-end 2017 financial results on Thursday, March 8, 2018, before the U.S. financial markets open. The Company's management will also host a conference call on the same day at 8:30 a.m. EST.

To access the live conference call, please dial (877) 868-1829 from the United States or (253) 237-1135 from other locations, shortly before 8:30 a.m. EST. A corresponding webcast of the conference call can be accessed by visiting https://www.webcaster4.com/Webcast/Page/1827/24814. The conference call can also be accessed on the Curis website at www.curis.com in the Investors section.

About Curis, Inc. 
Curis is a biotechnology company focused on the development and commercialization of innovative and effective drug candidates for the treatment of human cancers, including CUDC-907, which is being investigated in clinical studies in patients with lymphomas and solid tumors. Curis is also engaged in a broad collaboration with Aurigene in the areas of immuno-oncology and precision oncology. As part of this collaboration, Curis has exclusive licenses to oral small molecule dual antagonists of PD1 and VISTA, including PDL1/VISTA antagonist CA-170, and oral small molecule dual antagonists of PD1 and TIM3, including PDL1/TIM3 antagonist CA-327, as well as to molecules designed to inhibit the IRAK4 kinase, including CA-4948. CA-170 is currently undergoing testing in a Phase 1 trial in patients with advanced solid tumors and lymphomas. CA-4948 is currently undergoing testing in a Phase 1 trial in patients with lymphoma. Curis is also party to a collaboration with Genentech, a member of the Roche Group, under which Genentech and Roche are commercializing Erivedge® for the treatment of advanced basal cell carcinoma. For more information, visit Curis's website at www.curis.com.

View original content:http://www.prnewswire.com/news-releases/curis-to-release-fourth-quarter-and-year-end-2017-financial-results-and-hold-conference-call-on-march-8-2018-300606270.html

SOURCE Curis, Inc.

PR Newswire
www.prnewswire.com

Last updated on: 01/03/2018

Advertising
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.